Yahong Pharmaceutical (688176.SH): signed an exclusive license agreement with Theramex

Zhitongcaijing · 2d ago

Zhitong Financial App News, Yahong Pharmaceutical (688176.SH) issued an announcement. Recently, the company signed a conditional “Exclusive License Agreement” with Theramex HQ UK Limited (“Theramex”). According to the license agreement, Theramex will receive exclusive rights in APL-1702 (product name: Civita® /CEVIRA®) in European countries as well as Australia, New Zealand and Turkey. The company retains relevant interests in the rest of the world.

According to the agreement, the trading company will receive payments and tiered sales commissions including a down payment of $15 million, payment for recent registration milestones of $11 million, and commercialization milestones. The total transaction amount was over $250 million.